Other substances

VSV-eGFP-SARS-CoV-2

A replication-competent viral vector COVID-19 candidate vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

A replication-competent vesicular stomatitis virus (VSV)-based vaccine prepared by introducing a modified form of the SARS-CoV-2 spike gene in place of the native glycoprotein gene.

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis Spike protein Viral vector Animal model Mixed substance	BALB/c mice	15.92	The vaccine induced neutralizing antibodies against RBD of the SARS-CoV-2 spike protein, protected vaccinated mice and mice treated with immune sera of vaccinated mice from human SARS-CoV-2 infection and decreased SARS-CoV-2-induced lung inflammation and pathology.	Jul/30/2020

AI-suggested references

Link	Publication date
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.	Jan/27/2021
Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice.	Jul/30/2020
Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.	Jul/03/2020

Export (.csv)